Adalimumab in ulcerative colitis: Hypes and hopes

Expert Opinion on Biological Therapy

Volumn 11, Issue 1, 2011, Pages 109-116

  Fiorino, Gionata ^a,b   Peyrin Biroulet, Laurent ^c   Repici, Alessandro ^a   Malesci, Alberto ^a,d   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c INSERM   (France)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

adalimumab; anti TNF ; inflammatory bowel disease; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ARTHRALGIA; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DERMATITIS; DERMATOMYCOSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROENTERITIS; HEALING; HEARTBURN; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; INTESTINE MUCOSA; PNEUMONIA; PREDICTION; PROCTOCOLECTOMY; PROTEIN BLOOD LEVEL; PSORIASIS; REMISSION; REVIEW; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES AS TOPIC; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650050173     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.541435     Document Type: Review

References (31)

1. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68
2. Tracey D, Klareskog L, Sasso EH, et al. Tumour necrosis factor antagonist mechanism of action: A comprehensive review. Pharmacol Ther 2008;117:244-79 This article gives a detailed overview of anti-TNF-a.
3. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12:4807-12 This paper focuses on the recent advances in the knowledge of aetiology and pathogenesis of IBD.
4. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17
5. Murch SH, Braegger CP, Walker-Smith JA, MacDonald. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34;1705-9
6. Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: An anti-inflammatory multitasker. Dig Liver Dis 2008;40(Suppl 2):S225-8
7. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53 A key paper that analyses efficacy and safety of anti-TNF-a in Crohn's disease.
8. Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;233:2462-73 This is the first, to our knowledge, large randomized trial on infliximab in ulcerative colitis.
9. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am J Gastroenterol 2009;104:760-7
10. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;341:601-8 This article investigates the role of immunogenicity in loss of response to anti-TNF-a.
11. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355(9205):735-40
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33 This is the largest RCT on efficacy of adalimumab for the induction of remission in naïve patients with active CD.
13. Sandborn WJ, Hanauer SB, Rutgeerts P. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007;56:1232-9 This is the largest RCT on efficacy of adalimumab for the maintenance of remission in naïve patients with CD.
14. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007;146:829-38 This is the most important RCT on the efficacy of adalimumab in gaining response for patients that failed infliximab.
15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65 This large trial investigated the maintenance dose of adalimumab in patients with CD.
16. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40 This study showed that immunogenicity can result in loss of response to adalimumab.
17. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn's Colitis 2010;4(1):S5 This is the first RCT, to our knowledge, intended to investigate efficacy and safety of adalimumab in UC.
18. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 2007;13:2328-32 This is the first study, to our knowledge, on adalimumab as induction therapy in active UC.
19. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: A single-centre experience. Aliment Pharmacol Ther 2008;28:966-72 This is the first study, to our knowledge, on adalimumab as maintenance therapy in UC.
20. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7
21. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: Long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010;32:522-8
22. Taxonera C, Estelles J, Blanco I, et al. Adalimumab for ulcerative colitis patients previously treated with infliximab: Outcomes at short and long term and predictors of response. Gastroenterology 2010;138(5):S61
23. Hudis N, Rajca B, Polyak S, et al. The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology 2009;136(5):A661
24. Garcia-Bosch O, Aceituno M, Perez J, et al. Efficacy of adalimumab in the treatment of ulcerative colitis. J Crohn's Colitis 2010;4(1):S55
25. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-16
26. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60 This study shows that infliximab affects the reduction of colectomy rate in patients with active severe UC.
27. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
28. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11 This is a milestone among epidemiological studies of IBD.
29. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 2008;371(9613):660-7 This is the first study, to our knowledge, comparing 'top down' and 'step up' approaches in IBD.
30. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95 This is a large study evaluating the efficacy of combined immunosuppression versus monotherapy in CD.
31. Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807AM3). Bethesda, MD: Clinicaltrials.gov, 2007. Available from: Http://clinicaltrials. gov/ct2/show/NCT00537316? term=NCT00537316.&rank=1 [Last accessed 20 November 2010]